Category: Biotech
-
![Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights]()
Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights
Mountain Valley MD Holdings (MVMD.C) filed a cancer patent and is moving forward with preclinical trials with third party cancer research organizations (CROs) in triple-negative breast cancer, metastatic melanoma and lung carcinoma, according to a press release. The patent is called Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies, and involves solubilized ivermectin (also…
-
![I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms]()
I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan, but I’m going full editorial for this one as I have some experience with the topic. Through a series of psychedelic trips in my teen years,…
-
![Core One Labs (COOL.C) Completes Acquisition of Akome Biotech]()
Core One Labs (COOL.C) Completes Acquisition of Akome Biotech
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological illnesses. “Closing on Akome is an important step for the Company, as we have added an outstanding asset and a strong team. The drug formulations being…
-
![Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates]()
Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
![Core One Labs (COOL.C) takes their artificial psilocybin research to UBC]()
Core One Labs (COOL.C) takes their artificial psilocybin research to UBC
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing…
-
Xphyto (XPHY.C) bulks up executive team as Covid-19 ravages Europe
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
![Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules]()
Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin. A normal psilocybin experience will last around six hours, and can take up to an hour to begin. However, in their press release, Cybin notes that…
-
![Core One Labs (COOL.C) begins work on proprietary DMT production]()
Core One Labs (COOL.C) begins work on proprietary DMT production
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also known as the “spirit molecule”, is a naturally occurring psychedelic and is an active component in ayahuasca. It plays an important role in various rites of…
-
![Sixth Wave Innovations (SIXW.C) Enters LOI With Halucenex Life Sciences]()
Sixth Wave Innovations (SIXW.C) Enters LOI With Halucenex Life Sciences
Sixth Wave Innovations (SIXW.C) entered into a non-binding letter of intent (LOI) with Halucenex Life Sciences, a soon to be wholly-owned subsidiary of Cresco Pharma. According to the terms outlined in the LOI, Sixth Wave will utilize its Affinity™ in collaboration with Halucenex to explore the separation of compounds such as psilocybin, baeocystin, and others…
